Background
Tigecycline, a new agent against multidrug-resistant (MDR) bacteria, is especially licensed for use in complicated skin and soft tissue and intra-abdominal infections. We aimed to study the recent
in vitro
activity of tigecycline against MDR
Enterobacteriaceae
skin and soft tissue isolates.
Methods
Consecutive isolates (56
Escherichia coli
, 48
Klebsiella pneumoniae
) were subjected to tigecycline susceptibility testing by Ezy MIC test and interpreted as per European Committee on Antimicrobial Susceptibility Testing.
Results
The minimum inhibitory concentrations (MICs) of tigecycline ranged from 0.016 to 48 μg/mL, with MIC
50
0.19 μg/mL and MIC
90
1.0 μg/mL respectively. Seven (6.7%) isolates were resistant to tigecycline, all
K. pneumoniae
.
Conclusion
Tigecycline remains a viable therapeutic option against MDR isolates, with excellent
in vitro
activity against
E. coli
and promising activity against
K. pneumoniae
. However, the limited availability of alternate therapeutic armamentarium necessitates its use with extreme judiciousness along with continuous monitoring for the emergence and spread of resistance.